A prospect for pharmacogenomics in the interferon therapy of chronic viral hepatitis

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 2, 2003, Pages 149-151

  Yeh, Shiou Hwei ^a   Chen, Ding Shinn ^b,c   Chen, Pei Jer ^b,c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Antivirals; Genetic polymorphism; Hepatitis virus

Indexed keywords

ADEFOVIR DIPIVOXIL; ADENOSINE DEAMINASE; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; GAMMA INTERFERON; GUANOSINE TRIPHOSPHATASE; INITIATION FACTOR 2; INTERFERON; INTERLEUKIN 10; JANUS KINASE; LAMIVUDINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNOSE BINDING PROTEIN; NITRIC OXIDE SYNTHASE; NUCLEASE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; RIBAVIRIN; RIBONUCLEASE; STAT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA; VIRUS RNA;

ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CELLULAR IMMUNITY; CHRONIC HEPATITIS; DISEASE COURSE; DRUG SENSITIVITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; PHARMACOGENOMICS; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS GENOME; VIRUS HEPATITIS; VIRUS LOAD; VIRUS REPLICATION; VIRUS VIRULENCE;

EID: 84984549350     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg326     Document Type: Article

References (22)

1. Kao, J. H. & Chen, D. S. (2000). Overview of hepatitis B and C viruses. In Infectious Causes of Cancer: Targets for Intervention (Goedert, J. J., Ed.), pp. 313-30. Humana Press Inc., Totowa, NJ, USA.
2. Chen, P. J. & Chen, D. S. (1999). Hepatitis B virus infection and hepatocellular carcinoma: molecular genetics and clinical perspectives. Seminars in Liver Diseases 19, 253-62.
3. Hayashi, N. & Kasahara, A. (2002). Interferon for decreasing the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Oncology 62, 87-93.
4. Marcellin, P. (2002). Advances in therapy for chronic hepatitis B. Seminars in Liver Diseases 22, 33-6.
5. Chander, G., Sulkowski, M. S., Jenckes, M. W. et al. (2002). Treatment of chronic hepatitis C: a systematic review. Hepatology 36, Suppl., S135-44.
6. Liaw, Y. F. (2002). Therapy of chronic hepatitis B: current challenges and opportunities. Journal of Viral Hepatitis 9, 393-9.
7. McHutchison, J. G., Gordon, S. C., Schiff, E. R. et al. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine 339, 1485-92.
8. Kao, J. H., Chen, P. J., Lai, M. Y. et al. (2002). Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. Journal of Clinical Microbiology 40, 1207-9.
9. Kidd-Ljunggren, K., Miyakawa, Y. & Kidd, A. H. (2002). Genetic variability in hepatitis B viruses. Journal of General Virology 83, 1267-80.
10. Kao, J. H., Wu, N. H., Chen, P. J. et al. (2000). Hepatitis B genotypes and the response to interferon therapy. Journal of Hepatology 33, 998-1002.
11. Farci, P. & Purcell, R. H. (2000). Clinical significance of hepatitis C virus genotypes and quasispecies. Seminars in Liver Diseases 20, 103-26.
12. Hohler, T., Kruger, A., Gerken, G. et al. (1998). A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clinical and Experimental Immunology 111, 579-82.
13. Hohler, T., Kruger, A., Gerken, G. et al. (1998). Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. Journal of Medical Virology 54, 173-7.
14. Thursz, M. R. & Thomas, H. C. (1997). Host factors in chronic viral hepatitis. Seminars in Liver Diseases 17, 345-50.
15. Yee, L. J., Tang, J., Gibson, A. W. et al. (2001). Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 33, 708-12.
16. Hijikata, M., Mishiro, S., Miyamoto, C. et al. (2001). Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (-123 and -88) in vivo and in vitro. Intervirology 44, 379-82.
17. Sasaki, K., Tsutsumi, A., Wakamiya, N. et al. (2000). Mannose-binding lectin polymorphisms in patients with hepatitis C virus infection. Scandinavian Journal of Gastroenterology 35, 960-5.
18. Grandvaux, N., tenOever, B. R., Servant, M. J. et al. (2002). The interferon antiviral response: from viral invasion to evasion. Current Opinion in Infectious Diseases 15, 259-67.
19. Le Bon, A. & Tough, D. F. (2002). Links between innate and adaptive immunity via type I interferon. Current Opinion in Immunology 14, 432-6.
20. Aaronson, D. S. & Horvath, C. M. (2002). A road map for those who know JAK-STAT. Science 296, 1653-5.
21. Samuel, C. E. (2001). Antiviral actions of interferons. Clinical Microbiology Reviews 14, 778-809.
22. King, J. K., Yeh, S. H., Lin, M. W. et al. (2002). Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: a pilot study. Hepatology 36, 1416-24.